(ARGX) argenx - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US04016X1019

ARGX: Vygart, Vygart Hytrulo, Efgartigimod, Empasiprubart, Argx-119

argenx SE, a commercial-stage biopharmaceutical company, specializes in developing therapies for autoimmune diseases. Its lead products, VYGART and VYGART HYTRULO, are approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The companys pipeline includes efgartigimod, targeting multiple autoimmune conditions such as seronegative and ocular gMG, thyroid eye diseases, and lupus nephropathy. Other candidates like empasiprubart and ARGX-119 address rare neuromuscular disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). The company also develops ARGX-112, ARGX-114, and ARGX-115, focusing on Galectin-10 and IL-6 pathways. argenx collaborates with multiple industry and academic partners, including AbbVie, LEO Pharma, and Genmab, to advance its research and development efforts.

Founded in 2008 and headquartered in Amsterdam, the company has built a diverse portfolio targeting autoimmune and rare diseases. Its strategic collaborations span biotech, pharmaceutical, and academic institutions, enhancing its R&D capabilities. The companys focus on novel mechanisms, such as targeting FcRn and IL-6, positions it as a key player in the autoimmune disease space. With a strong emphasis on innovation and partnerships, argenx continues to expand its pipeline and commercial footprint globally.

Based on and , the 3-month outlook for ARGX is as follows: - Price Action: The stock is likely to trade between $580 and $620, with potential resistance at $607.30 (SMA 50) and support at $573.79 (SMA 200). - Volatility: Average True Range (ATR) of 21.70 suggests moderate price fluctuations. - Momentum: The recent price of $596.20 above the SMA 20 ($583.41) indicates near-term bullish momentum. - Valuation: High P/S (14.82) and P/B (6.06) ratios suggest elevated expectations for future growth, which could lead to volatility if earnings fail to meet expectations. - Earnings Sentiment: The forward P/E of 80.65 reflects strong growth expectations, but investors may remain cautious due to the high valuation multiples.

Additional Sources for ARGX Stock

ARGX Stock Overview

Market Cap in USD 33,314m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2017-05-18

ARGX Stock Ratings

Growth Rating 90.7
Fundamental 63.1
Dividend Rating 0.0
Rel. Strength 69.5
Analysts 4.5/5
Fair Price Momentum 702.45 USD
Fair Price DCF -

ARGX Dividends

No Dividends Paid

ARGX Growth Ratios

Growth Correlation 3m -86%
Growth Correlation 12m 87.1%
Growth Correlation 5y 92.2%
CAGR 5y 32.40%
CAGR/Max DD 5y 0.85
Sharpe Ratio 12m 0.85
Alpha 53.61
Beta 0.242
Volatility 42.75%
Current Volume 224.5k
Average Volume 20d 435.7k
What is the price of ARGX stocks?
As of April 24, 2025, the stock is trading at USD 594.65 with a total of 224,496 shares traded.
Over the past week, the price has changed by +1.20%, over one month by -2.19%, over three months by -8.82% and over the past year by +58.54%.
Is argenx a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, argenx (NASDAQ:ARGX) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARGX as of April 2025 is 702.45. This means that ARGX is currently undervalued and has a potential upside of +18.13% (Margin of Safety).
Is ARGX a buy, sell or hold?
argenx has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ARGX.
  • Strong Buy: 13
  • Buy: 7
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ARGX stock price target?
According to ValueRays Forecast Model, ARGX argenx will be worth about 759.5 in April 2026. The stock is currently trading at 594.65. This means that the stock has a potential upside of +27.72%.
Issuer Forecast Upside
Wallstreet Target Price 786.9 32.3%
Analysts Target Price 674.5 13.4%
ValueRay Target Price 759.5 27.7%